Comparative Pharmacology
Head-to-head clinical analysis: CARDIOLITE versus NEPHROSCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOLITE versus NEPHROSCAN.
CARDIOLITE vs NEPHROSCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium Tc-99m sestamibi is a lipophilic cation that accumulates in myocardial cells via passive diffusion across the sarcolemmal and mitochondrial membranes. Its uptake is proportional to myocardial blood flow and viability, allowing for imaging of myocardial perfusion.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
CARDIOLITE (Technetium-99m sestamibi) is administered intravenously. For myocardial perfusion imaging, adult dose: 10-40 mCi (370-1480 MBq), administered as a single bolus.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours; prolonged in elderly and renal impairment (up to 12-16 hours).
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 85-90% as unchanged drug; fecal: <5%
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical